Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
The only caveat is that, as part of the deal, Elixir II will require financial assistance, and this will come from the shares that Willowglen is getting in Elixir II, which will be pledged to a bank as a share charge, as will the shares of Elixir I.
This assistance will help Elixir II borrow S$35mil to help pay for the transaction. Shareholders will need to scrutinise and weigh whether this deal is good for them, as this share charge will remain in effect until Elixir II has fully settled the banking facility, after which these shares will be released to Willowglen free of encumbrances.
But what happens till then? What benefits can Willowglen reap from this deal?
This structure isn't a weakness, it's a smart, capital-efficient move. The share charge is a normal way to finance things, and it doesn't take away Willowglen's profits from Elixir II. Instead of worrying about temporary issues, shareholders should look at whether the asset itself makes more money than it costs to finance. If it does, this deal boosts long-term value without diluting shares or draining cash.
The emphasis on the share charge may be misdirected. The true significance lies in the quality and return potential of the business Willowglen intends to acquire. While financing arrangements of this nature are typical and transient, the inherent value of the asset is what ultimately determines shareholder returns. Should Elixir II generate robust and consistent cash flow, this transaction would be considered value-enhancing, irrespective of any temporary encumbrance.
